These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7946573)

  • 41. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
    Wagener DJ; Hoogenraad WJ; Rougier P; Lusinchi A; Taal BG; Veenhof CH; de Graeff A; Conroy T; Curran D; Sahmoud T; Wils J
    Eur J Cancer; 1996 Jul; 32A(8):1310-3. PubMed ID: 8869091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Keys to personalized care in pancreatic oncology.
    Crane CH; Iacobuzio-Donahue CA
    J Clin Oncol; 2012 Nov; 30(33):4049-50. PubMed ID: 23045599
    [No Abstract]   [Full Text] [Related]  

  • 43. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma.
    Raderer M; Pidlich J; Müller C; Pfeffel F; Kornek GV; Hejna M; Scheithauer W
    Eur J Cancer; 1996 Dec; 32A(13):2366-8. PubMed ID: 9038625
    [No Abstract]   [Full Text] [Related]  

  • 45. [Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy].
    Sakata Y; Chiba Y; Sato T; Kimura M; Fukushi G; Matsukawa M; Wada K; Aoyama H; Sawada Y; Fukushi M
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):195-201. PubMed ID: 1736831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of preoperative chemotherapy on apoptosis and tissues of pancreatic adenocarcinoma].
    Liao Q; Zhao Y; Cai L; Chen J; Liu T; Zhu Y
    Zhonghua Wai Ke Za Zhi; 1999 Mar; 37(3):146-8, 7. PubMed ID: 11829805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perspectives in chemotherapy of pancreatic cancer.
    Klapdor R
    Eur J Surg Oncol; 1991 Apr; 17(2):153-66. PubMed ID: 1707835
    [No Abstract]   [Full Text] [Related]  

  • 48. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma.
    Swarovsky B; Wolf M; Havemann K; Arnold R
    Oncology; 1993; 50(4):226-9. PubMed ID: 8497375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pancreatic cancer: how can we progress?
    Casper ES
    Eur J Cancer; 1993; 29A(2):171-2. PubMed ID: 8422277
    [No Abstract]   [Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult.
    Boeck S; Haas M; Ormanns S; Kruger S; Siveke JT; Heinemann V
    Br J Cancer; 2014 Oct; 111(8):1675-6. PubMed ID: 24642615
    [No Abstract]   [Full Text] [Related]  

  • 51. Stellate cells, a point of light in the dark night of pancreatic cancer.
    Ramírez N; Viúdez A; Hernández-García I; Guerrero D; Gómez-Dorronsoro M; Herrera FJ; Vila J; Beloki L; Ciaúrriz M; Mansilla C; Vera R
    Br J Cancer; 2014 Oct; 111(8):1676-7. PubMed ID: 24642614
    [No Abstract]   [Full Text] [Related]  

  • 52. Delicate Balance Between Quality and Quantity of Life: Palliative Chemotherapy for Metastatic Pancreatic Adenocarcinoma.
    Warner-Cohen J; Saif MW
    JCO Oncol Pract; 2020 Dec; 16(12):845. PubMed ID: 32780639
    [No Abstract]   [Full Text] [Related]  

  • 53. Targeting Stroma: A Tale of Caution.
    Wang-Gillam A
    J Clin Oncol; 2019 May; 37(13):1041-1043. PubMed ID: 30860950
    [No Abstract]   [Full Text] [Related]  

  • 54. Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma.
    Di Bartolomeo M; Zampino MG; Di Leo A; Bajetta E
    Eur J Cancer; 1993; 29A(8):1215-6. PubMed ID: 8518036
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W
    Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy of locally advanced pancreatic cancer with FOLFIRINOX].
    Strobel O; Büchler MW
    Chirurg; 2016 Aug; 87(8):699. PubMed ID: 27418266
    [No Abstract]   [Full Text] [Related]  

  • 57. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group.
    Abad A; Masuti B; Camps C; Font A; Balañá C; Vicent JM; Sánchez JJ
    Eur J Cancer; 1994; 30A(7):1043. PubMed ID: 7946573
    [No Abstract]   [Full Text] [Related]  

  • 58. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
    Wils J; Bleiberg H; Buyse M; Wagener DT; Splinter T; Veenhof C; Herben M; Duez N
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1119-20. PubMed ID: 2759166
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.